ArticleScientific reports2025
High CD36 expression in the tumor microenvironmental vasculature correlates with unfavorable overall survival in high grade serous ovarian cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Lipids grease the chain of cancer progression.Trends in cancer · 2026Review
- The Role of Low CD36 Expression in the Development of Non-Small Cell Lung Cancer and Its Potential for Therapy.Cancers · 2026Review
- Feasibility of vinegar processing of toxic herbs in Shi-Zao-Tang: toxicity reduction, efficacy preservation in malignant ascites rats and underlying pharmacodynamic mechanisms.Chinese medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The scavenger receptor CD36 has gained increasing interest in cancer research, with various functions in cell metabolism, angiogenesis, and immune response. This study aimed to investigate the molecular role of CD36 expression on tumor vasculature of advanced high-grade serous ovarian cancer (HGSOC) tissues and its prognostic implication. Immunohistochemical staining for CD36 was performed on whole tissue slides of 109 patients with advanced HGSOC. Patients were divided into two groups based on CD36 expression, i.e. positive versus negative, and correlated to clinicopathologic and survival data. RNA sequencing, metabolomics, and proteomics data were correlated to the CD36 expression within a subpopulation. CD36 expression in tumor vasculature was significantly associated with unfavorable overall survival (OS), both in univariate (HR 1.71, p = 0.039) and multiple Cox regression analyses (HR 1.91, p = 0.021), considering age, FIGO stage, postoperative residual tumor, and bevacizumab treatment as covariates. Positive CD36 expression was significantly associated with postoperative residual tumor, reflecting high tumor-burden. (p = 0.042). RNA sequencing from isolated tumor cells revealed an activated 'regulation of lipolysis in adipocytes' pathway significantly associated with CD36 expression. Co-association gene expression network analysis revealed increased ribosomal activity and protein translation in tumor cells of CD36-positive samples. Proteomics analysis of ascites showed three overexpressed proteins involved in lipid metabolism (LCN2, CFHR1, and CFHR4) out of 21 significantly deregulated proteins. Metabolomic analyses of serum showed a significant decrease of 60 glycerophospholipids (mainly unsaturated ones) and eight amino acids, four essential proteinogenic, in patients with CD36 positive vessels. CD36 intratumoral vessel expression was associated with unfavorable OS in patients with advanced HGSOC. Our analyses support the role of CD36 in tumor metabolism, possibly via CD36
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.